The Anti-tumour Effects of the Prodrugs N-l-leucyl-doxorubicin and Vinblastine-isoleucinate in Human Ovarian Cancer Xenografts

Overview

Journal Br J Cancer

Specialty Oncology

Date 1992 Dec 1

PMID 1457343

Citations 5

Authors

E Boven

H R Hendriks

C A Erkelens

H M Pinedo

Affiliations

Soon will be listed here.

Abstract

N-l-leucyl-doxorubicin and vinblastine-isoleucinate can be considered as relatively non-toxic prodrugs from doxorubicin and vinblastine, respectively. A comparative analysis was carried out of the anti-tumour activity of the four compounds as well as vintriptol in four human ovarian cancer xenografts different in histology, growth rate and chemosensitivity. Injections were given i.v. weekly twice into mice bearing well-established s.c. tumours. At equitoxic doses, the amount of drug administered for N-l-leucyl-doxorubicin and vinblastine-isoleucinate was respectively 3-fold and 2-fold higher than the doses of the parent compound. N-l-leucyl-doxorubicin induced a growth inhibition > 50% in three out of four human ovarian cancer lines. The anti-tumour effects obtained were significantly better (P < 0.01) than in the case of doxorubicin. Vinblastine-isoleucinate studied in two of these lines could induce a growth inhibition of > 50%. This prodrug appeared slightly less effective than vinblastine. Insignificant growth inhibition (< 50%) was obtained by vintriptol.

Citing Articles

Protease-activated drug development.

Choi K, Swierczewska M, Lee S, Chen X Theranostics. 2012; 2(2):156-78.

PMID: 22400063 PMC: 3296471. DOI: 10.7150/thno.4068.

L-histidine-based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity.

Oh K, Lee E, Kim D, Bae Y Int J Pharm. 2008; 358(1-2):177-83.

PMID: 18407443 PMC: 3108151. DOI: 10.1016/j.ijpharm.2008.03.003.

A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.

Houba P, Boven E, Leenders R, Scheeren J, Pinedo H, Haisma H Br J Cancer. 2001; 84(4):550-7.

PMID: 11207053 PMC: 2363760. DOI: 10.1054/bjoc.2000.1640.

The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

Houba P, Boven E, Erkelens C, Leenders R, Scheeren J, Pinedo H Br J Cancer. 1998; 78(12):1600-6.

PMID: 9862570 PMC: 2063245. DOI: 10.1038/bjc.1998.729.

Vinblastine and 5-fluorouracil sensitivity of xenografts of four pancreatic ductal adenocarcinomas: is there a correlation with histological and cytological tumour differentiation?.

Vergeylen A, Kloppel G Virchows Arch. 1995; 427(3):317-22.

PMID: 7496603 DOI: 10.1007/BF00203401.

References

Hendriks H, Langdon S, Berger D, Breistol K, Fiebig H, Fodstad O . Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts. Eur J Cancer. 1992; 28A(4-5):767-73. DOI: 10.1016/0959-8049(92)90112-f. View

JOHNSON I, Armstrong J, Gorman M, BURNETT Jr J . THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963; 23:1390-427. View

Boven E, Schluper H, Erkelens C, Pinedo H . Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. Eur J Cancer. 1990; 26(9):983-6. DOI: 10.1016/0277-5379(90)90626-5. View

Maciewicz R, Wardale R, Etherington D, Paraskeva C . Immunodetection of cathepsins B and L present in and secreted from human pre-malignant and malignant colorectal tumour cell lines. Int J Cancer. 1989; 43(3):478-86. DOI: 10.1002/ijc.2910430323. View

Waller D, George C . Prodrugs. Br J Clin Pharmacol. 1989; 28(5):497-507. PMC: 1380009. DOI: 10.1111/j.1365-2125.1989.tb03535.x. View

Thorpe S, ROCHEFORT H, Garcia M, Freiss G, Christensen I, Khalaf S . Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989; 49(21):6008-14. View

Boven E, Winograd B, Fodstad O, Lobbezoo M, Pinedo H . Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol. 1988; 24(3):567-73. DOI: 10.1016/s0277-5379(98)90039-6. View

Bhushana Rao K, Collard M, Dejonghe J, Atassi G, Hannart J, Trouet A . Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias. J Med Chem. 1985; 28(8):1079-88. DOI: 10.1021/jm00146a017. View

Boven E, van der Vijgh W, Nauta M, Schluper H, Pinedo H . Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res. 1985; 45(1):86-90. View

10.

Boven E, Nauta M, Schluper H, Elferink F, van der Vijgh W, Pinedo H . Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. Eur J Cancer Clin Oncol. 1985; 21(10):1253-60. DOI: 10.1016/0277-5379(85)90023-9. View

11.

Jaenke R, Trouet A . Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res. 1980; 40(10):3530-6. View

12.

Baurain R, Trouet A . Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice. Cancer Chemother Pharmacol. 1982; 8(2):193-7. DOI: 10.1007/BF00255483. View

13.

Young R, Ozols R, Myers C . The anthracycline antineoplastic drugs. N Engl J Med. 1981; 305(3):139-53. DOI: 10.1056/NEJM198107163050305. View

14.

Masquelier M, Baurain R, Trouet A . Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J Med Chem. 1980; 23(11):1166-70. DOI: 10.1021/jm00185a003. View

15.

Baurain R, Masquelier M, Trouet A . Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo. J Med Chem. 1980; 23(11):1171-4. DOI: 10.1021/jm00185a004. View

16.

Oosterkamp H, Vlasveld L, Wanders J, Beijnen J, van Tellingen O, Dubbelman A . Phase I study of vintriptol, a tryptophan ester of vinblastine. Eur J Cancer. 1991; 27(10):1222-6. DOI: 10.1016/0277-5379(91)90085-r. View